Download PDF
Pharmacopsychiatry 2022; 55(01): 5-6
DOI: 10.1055/a-1720-8855
Editorial

Covid-19: Contributions from Psychopharmacology

Michael Bauer
1   Department of Psychiatry and Psychotherapy, Medical Faculty, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany
,
Georg Juckel
2   Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University Hospital, Ruhr-Universität Bochum, Bochum, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

The COVID-19 pandemic is causing a major burden on personal health, healthcare systems and the global economy. For the last two years the COVID-19 pandemic has dramatically changed our lives in many personal and professional areas. For millions of us, due to infection rates, but also to protection measures such as lockdowns the corona pandemic has significantly changed the way we work, how we live, and how we interact with technology. In addition to the development of effective vaccines, anti-viral and anti-inflammation strategies are of eminent importance to treat people with acute infection or at least prevent serious negative outcomes. In contrast to the fast development of several effective vaccines that were remarkably available already after one year of the pandemic, novel effective anti-viral compounds are still in development. The only currently used effective medications against severe SARS-CoV-2 virus infection are corticosteroids [1].



Publication History

Article published online:
25 January 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mueller JK, Riederer P, Mueller WE. Neuropsychiatric drugs against COVID-19: What is the clinical evidence?. Pharmacopsychiatry 2022; 55: 7-15
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Murru A, Manchia M, Hajek T. et al. for the International Group for The Study of Lithium Treated Patients (IGSLi) Lithium's Antiviral Effects: A Potential Drug for CoViD-19 Disease?. Int J Bipolar Disord 2020; 8: 21
    CrossrefPubMedSearch in Google Scholar
  • 3 Liu X, Verma A, Garcia G. et al. Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition. Proc Natl Acad Sci USA. 2021; 118: e2113401118
    CrossrefPubMedSearch in Google Scholar
  • 4 Khosravi M. Candidate Psychotropics against SARS-CoV-2: A Narrative Review. Pharmacopsychiatry 2022; 55: 16-23
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Nykamp MJ, Zorumski CF, Reiersen AM. et al. Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention. Pharmacopsychiatry 2022; 55: 24-29
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Bonnet U, Juckel G, Scherbaum N. et al. Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?. Pharmacopsychiatry 2021; 54: 142-143
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Bonnet U, Claus B, Schaefer M. et al. Impact of Psychiatric and Related Somatic Medications on the Duration and Severity of COVID-19: A Retrospective Explorative Multi-center Study from the German Metropolitan Ruhr-area. Pharmacopsychiatry 2022; 55: 30-39
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Plasencia-García BO, Rico-Rangel MI, Rodríguez-Menéndez G. et al. Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases. Pharmacopsychiatry 2022; 55: 40-47
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Veerman SRT, Bogers JPAM, Cohen D. et al. COVID-19: Risks, Complications, and Monitoring in Patients on Clozapine. Pharmacopsychiatry 2022; 55: 48-56
    Thieme ConnectPubMedSearch in Google Scholar